Delcath Systems (NASDAQ:DCTH) Releases Quarterly Earnings Results, Beats Expectations By $0.26 EPS

Delcath Systems (NASDAQ:DCTH) released its quarterly earnings data on Monday. The company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.26, FiscalAI reports. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%. The company had revenue of $35.10 million during the quarter, compared to the consensus estimate of $25.99 million.

Delcath Systems Price Performance

Shares of DCTH stock opened at $14.93 on Monday. The firm has a market cap of $518.06 million, a price-to-earnings ratio of 1,494.49 and a beta of 0.62. The company’s 50 day moving average is $15.45 and its 200 day moving average is $12.44. Delcath Systems has a 52-week low of $8.12 and a 52-week high of $17.42.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Zacks Research lowered shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 6th. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a report on Friday, August 7th. Wall Street Zen upgraded shares of Delcath Systems from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings cut shares of Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. Finally, BTIG Research upped their target price on shares of Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $26.67.

Delcath Systems Company Profile

Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.

Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.

Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.